Dominique Vidaud

List of Publications by Year
in descending order

64 papers	4,332 citations	117625 34 h-index	114465 63 g-index
66 all docs	66 docs citations	66 times ranked	6264 citing authors

#	Article	IF	Citations
1	Characterization of a Germ-Line Deletion, Including the Entire INK4/ARF Locus, in a Melanoma-Neural System Tumor Family: Identification of ANRIL, an Antisense Noncoding RNA Whose Expression Coclusters with ARF. Cancer Research, 2007, 67, 3963-3969.	0.9	582
2	Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications. Clinical Chemistry, 1999, 45, 1148-1156.	3.2	235
3	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Human Mutation, 2010, 31, E1506-E1518.	2.5	208
4	Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. International Journal of Cancer, 1998, 78, 661-666.	5.1	191
5	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of Hepatology, 2012, 56, 527-532.	3.7	165
6	Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology, 2005, 129, 2064-2075.	1.3	161
7	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nature Genetics, 2015, 47, 1334-1340.	21.4	152
8	Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology, 2005, 332, 130-144.	2.4	145
9	NF1 Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience. Human Mutation, 2013, 34, 1510-1518.	2.5	140
10	Neurofibromatosis type 1: from genotype to phenotype. Journal of Medical Genetics, 2012, 49, 483-489.	3.2	133
11	Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Human Molecular Genetics, 2009, 18, 2768-2778.	2.9	129
12	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
13	Liver Iron, HFE Gene Mutations, and Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis. Gastroenterology, 2008, 134, 102-110.	1.3	115
14	Mutations in the catalytic domain of human coagulation factor IX: Rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior. Genomics, 1989, 4, 266-272.	2.9	110
15	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Journal of the National Cancer Institute, 2011, 103, 1713-1722.	6.3	106
16	Haemophilia B Due to a De Novo Insertion of a Human-Specific Alu Subfamily Member within the Coding Region of the Factor IX Gene. European Journal of Human Genetics, 1993, 1, 30-36.	2.8	106
17	Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. Human Genetics, 1996, 98, 696-699.	3.8	97
18	Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?. European Journal of Human Genetics, 2015, 23, 596-601.	2.8	97

#	Article	IF	Citations
19	Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Molecular Cancer, 2004, 3, 20.	19.2	85
20	Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nature Genetics, 2006, 38, 1419-1423.	21.4	76
21	Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology, 2015, 149, 1017-1029.e3.	1.3	76
22	Genetic Polymorphisms in Antioxidant Enzymes Modulate Hepatic Iron Accumulation and Hepatocellular Carcinoma Development in Patients with Alcohol-Induced Cirrhosis. Cancer Research, 2006, 66, 2844-2852.	0.9	70
23	Analyses ofMYC,ERBB2, andCCND1Genes in Benign and Malignant Thyroid Follicular Cell Tumors by Real-Time Polymerase Chain Reaction. Thyroid, 2001, 11, 147-152.	4.5	60
24	SETD2andDNMT3Ascreen in the Sotos-like syndrome French cohort. Journal of Medical Genetics, 2016, 53, 743-751.	3.2	54
25	Confirmation of mutation landscape of NF1â€associated malignant peripheral nerve sheath tumors. Genes Chromosomes and Cancer, 2017, 56, 421-426.	2.8	54
26	Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1. Clinical Cancer Research, 2007, 13, 398-407.	7.0	48
27	Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology, 2018, 20, 917-929.	1.2	48
28	Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. Molecular Medicine, 2011, 17, 79-87.	4.4	46
29	MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics, 2013, 14, 473.	2.8	46
30	The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. Clinical Cancer Research, 2014, 20, 358-371.	7.0	44
31	First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis. European Journal of Human Genetics, 2012, 20, 277-282.	2.8	42
32	SPRED1 disorder and predisposition to leukemia in children. Blood, 2009, 114, 1131-1131.	1.4	40
33	Echinococcus multilocularis:Microsatellite Polymorphism in U1 snRNA Genes. Experimental Parasitology, 1996, 82, 324-328.	1.2	39
34	Moyamoya syndrome in children with neurofibromatosis type 1: Italianâ€"French experience. American Journal of Medical Genetics, Part A, 2017, 173, 1521-1530.	1.2	36
35	Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis. British Journal of Haematology, 1993, 84, 662-669.	2.5	35
36	Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. Clinical Cancer Research, 2004, 10, 3763-3771.	7.0	34

#	Article	IF	Citations
37	Novel recurrent nonsense mutation causing neurofibromatosis type 1 (NF1) in a family segregating both NF1 and Noonan syndrome. , 1998, 75, 265-272.		31
38	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. Journal of Molecular Diagnostics, 2009, 11, 524-529.	2.8	31
39	Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. European Journal of Human Genetics, 2008, 16, 1459-1466.	2.8	30
40	A novel mutation in the neurofibromatosis type 1 (NF1) gene promotes skipping of two exons by preventing exon definition11Edited by M. Yaniv. Journal of Molecular Biology, 2001, 307, 1261-1270.	4.2	29
41	Non-invasive prenatal diagnosis of paternally inherited disorders from maternal plasma: detection of NF1 and CFTR mutations using droplet digital PCR. Clinical Chemistry and Laboratory Medicine, 2018, 56, 728-738.	2.3	26
42	Prenatal Detection by Real-Time Quantitative PCR and Characterization of a New CFTR Deletion, 3600+15kbdel5.3kb (or CFTRdele19). Clinical Chemistry, 2000, 46, 1417-1420.	3.2	25
43	Significant gene expression differences in histologically Ã¢Â€ÂœNormalÃ¢Â€Â•liver biopsies: Implications for control tissue. Hepatology, 2008, 48, 953-962.	7.3	25
44	Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. Molecular Brain Research, 2003, 114, 55-64.	2.3	24
45	The CGA gene as new predictor of the response to endocrine therapy in ERÎ±-positive postmenopausal breast cancer patients. Oncogene, 2001, 20, 6955-6959.	5.9	22
46	Differential Expression ofCCN1/CYR61,CCN3/NOV,CCN4/WISP1, andCCN5/WISP2in Neurofibromatosis Type 1 Tumorigenesis. Journal of Neuropathology and Experimental Neurology, 2010, 69, 60-69.	1.7	16
47	Structure of the Echinococcus multilocularis U1 snRNA gene repeat. Molecular and Biochemical Parasitology, 1991, 46, 285-292.	1.1	15
48	NF1 single and multi-exons copy number variations in neurofibromatosis type 1. Journal of Human Genetics, 2015, 60, 221-224.	2.3	15
49	Severe Phenotype in Patients with Large Deletions of NF1. Cancers, 2021, 13, 2963.	3.7	15
50	NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas. Cancer Medicine, 2019, 8, 4330-4337.	2.8	14
51	Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling. Human Genetics, 1993, 91, 241-4.	3.8	10
52	SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. Human Pathology, 2011, 42, 434-443.	2.0	10
53	Sporadic NF1 mutation associated with a de-novo 20q11.3 deletion explains the association of unusual facies, Moyamoya vasculopathy, and developmental delay, reported by Bertoli et al. in 2009. Clinical Dysmorphology, 2013, 22, 42-43.	0.3	8
54	Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities. Orphanet Journal of Rare Diseases, 2016, 11, 101.	2.7	7

#	Article	IF	Citations
55	Relevance of MPNST cell lines as models for NF1 associated-tumors. Journal of Neuro-Oncology, 2013, 114, 353-355.	2.9	5
56	Droplet digital PCR, a new approach to analyze fetal DNA from maternal blood: application to the determination of fetal RHD genotype. Annales De Biologie Clinique, 2016, 74, 269-277.	0.1	5
57	One NF1 Mutation may Conceal Another. Genes, 2019, 10, 633.	2.4	5
58	Novel approach to quantitative polymerase chain reaction using realâ€time detection: Application to the detection of gene amplification in breast cancer. International Journal of Cancer, 1998, 78, 661-666.	5.1	5
59	Two independent de novo mutations as a cause for neurofibromatosis type 1 and Noonan syndrome in a single family. American Journal of Medical Genetics, Part A, 2012, 158A, 2290-2291.	1.2	4
60	NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. Neuro-Oncology Advances, 2020, 2, i98-i106.	0.7	4
61	RAS MAPK inhibitors deregulation in leukemia. Oncoscience, 2015, 2, 930-931.	2.2	4
62	Neurofibromatosis Type 1 Molecular Diagnosis: The RNA Point of View. EBioMedicine, 2016, 7, 21-22.	6.1	3
63	Modifier Genes in NF1. , 2012, , 269-285.		1
64	Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 739-743.	2.4	0